Neoplastic Meningitis from Breast Cancer: Feasibility and Activity of Long-term Intrathecal Liposomal Ara-C Combined with Dose-dense Temozolomide
|
|
- Jayson Lawson
- 5 years ago
- Views:
Transcription
1 Neoplastic Meningitis from Breast Cancer: Feasibility and Activity of Long-term Intrathecal Liposomal Ara-C Combined with Dose-dense Temozolomide A-L. HOFFMANN 1, J-H. BUHK 2 and H. STRIK 3 Departments of 1 Neurology and 2 Neuroradiology, University Medicine Göttingen, Göttingen; 3 Department of Neurology, University of Marburg, Marburg, Germany Abstract. Background: Patients with neoplastic meningitis (NM) from breast cancer have a median survival of 4-8 months with specific treatment. Here, good tolerance and long-term stabilization with combined intrathecal liposomal cytarabine (Ara-C), which is probably the most promising drug for intrathecal chemotherapy to date, near-continuous temozolomide and radiotherapy is reported in two patients with leptomeningeal and solid central nervous system (CNS) metastases from breast cancer. Case Reports: A 42- and a 43-year-old female presented with NM and disseminated CNS metastases from human epidermal growth factor receptor type 2 (Her2)-positive breast cancer. After irradiation of the symptomatic sites, intrathecal liposomal Ara-C every 2-4 weeks was combined with temozolomide 100 mg/m 2 day 1-5/7. Cerebrospinal fluid (CSF) cytology and neurological symptoms improved in both patients and stabilized for several months. The patients survived 10 and 17 months after diagnosis of NM, without signs of neurological toxicity. Conclusion: Intensive treatment is complicated by extensive pre-treatment and the lack of active CNS-penetrating systemic drugs. The long-term results with up to 17 intrathecal injections of liposomal Ara- C show that this treatment regimen is feasible and welltolerated. The stabilization of both patients indicates activity of this combined intrathecal and systemic regimen that is based on long-term exposure of the tumour cells to both Ara-C and temozolomide. The results need to be confirmed prospectively. Correspondence to: PD Dr. Herwig Strik, Department of Neurology, University of Marburg, Rudolf Bultmann Str. 8, D Marburg, Germany. Tel: , Fax: , strik@med.uni-marburg.de Key Words: Breast cancer, leptomeningeal disease, neoplastic meningitis, chemotherapy, temozolomide, DepoCyte, liposomal Ara-C. Since the introduction of trastuzumab, the survival of human epidermal growth factor receptor type 2 (Her2)-positive breast cancer patients has improved. The rate of central nervous system (CNS) involvement, however, is increasing. This may not only be caused by the longer survival with improved control of the systemic disease, but also because trastuzumab, an antibody of relatively large-molecular size, cannot penetrate the blood-brain barrier (1). CNS involvement, whether solid or in the cerebrospinal fluid (CSF), is a severe complication that usually occurs in late stages of the disease. Neoplastic meningitis (NM) typically presents with multifocal symptoms at multiple levels of the CNS. Symptoms often include headache, nausea, cranial nerve palsy, radicular symptoms or paraparesis (2, 3). Neurological impairment most often progresses very rapidly. The prognosis of patients with CSF dissemination and solid CNS metastases from breast cancer is poor. Effective therapy is complicated by the intense pre-treatment and the lack of active CNS-penetrating systemic drugs. Without specific treatment, the median survival of NM from solid tumours is 4-6 weeks (4, 5). Intensive treatment results in a median overall survival of 4-8 months, depending on the histology and dissemination of the primary tumour, the clinical condition, and therapy schedule (6, 7). Breast cancer seems to be the solid neoplasm responding best to therapy (3, 8). Since there is no standard therapy and the individual stage of the primary neoplasm and systemic metastases has to be considered, the treatment has to be individualized. Therapeutic modalities include intrathecal and systemic chemotherapy, radiotherapy and, in the case of increased intracranial pressure or for the placement of a ventricular reservoir, surgery (9). The drugs most commonly used for intrathecal therapy are methotrexate, cytarabine (Ara-C) and thiotepa. These substances have a half-life of only a few hours within the CSF (10). Liposomal encapsulation of Ara-C (DepoCyte ) results in a sustained-release and prolongs the half-life of Ara-C within the CSF from 3.4 to 140 hours and maintains cytotoxic concentrations for at least 21 days (11), thus intrathecal /2009 $
2 administration is required only every 2-4 weeks (12). Such prolonged exposure of tumor cells to chemotherapy may lead to improved efficacy (13, 14). Due to the rare occurrence and the lack of prospective, randomized studies, the relevance of the treatment options, systemic and intra-csf chemotherapy and radiotherapy, is not yet well determined. Moreover, CSF involvement only rarely occurs in isolation, but is often associated with solid systemic and CNS metastasis. Even after successful therapy of CSF involvement, progression of solid metastases may lead to clinical deterioration and death. Therefore, reports on the value of the respective treatment modalities are difficult to consider. The value of each treatment option has to be evaluated in the context of the entire disease and the whole therapeutic concept (9). Although intrathecal application of chemotherapy achieves the highest concentrations in the CSF and is cleared more slowly from the CSF space than after systemic application (15), its efficacy for neoplastic meningitis from solid neoplasms remains unclear. One possible factor reducing its effect is the limited diffusion into solid tumour manifestations lining the CSF spaces. Distant solid spinal or cerebral metastases cannot be reached by intrathecal chemotherapy, although CNS metastases often coexist and also require treatment. Therefore, combined intrathecal and systemic chemotherapy may be the most promising regimen (13). The majority of systemically applied drugs for the treatment of metastatic breast cancer, including trastuzumab, do not cross the blood-brain barrier. Temozolomide, an orally available alkylating agent with favorable toxicity profile, is effective against malignant gliomas and melanomas. Since it penetrates the blood-brain barrier, it seems to be an attractive agent to treat cerebral metastases. Only single reports exist on the use of temozolomide in breast cancer, either with conventional application day 1-5/28 (16-18) or with a dose-dense schedule (19). In relapsed glioblastoma, we observed activity of a rechallenge with temozolomide in a dose-dense regimen day 1-21/28 at 100 mg/m 2 despite failure of the conventional application (20). Moreover, we observed the feasibility of application day 1-5/7 at 100 mg/m 2 (TEGWONDO TEmozolomide Glioma WOrkiNg day DOse-dense schedule). The near-continuous exposure of tumor cells to both liposomal Ara-C and temozolomide in patients with solid CNS metastases and CSF dissemination could be a promising strategy. Here the tolerance and long-term effectiveness of this strategy in two heavily pretreated patients with solid CNS metastases and NM from Her2-positive breast cancer is reported. Case Reports Case 1. A 43-year-old woman suffering from Her2-positive breast cancer since March 2001 received 4 cycles ACchemotherapy from April to July that year. A local relapse was surgically treated in October From January 2003 to May 2006, tamoxifen and gosereline (Zoladex ) were administered. 1 cycle of paclitaxel (Taxol ) was given and from June 2006, she received trastuzumab. In July 2006, metastases to the cervical spine were stabilized operatively and irradiated. In January 2007, she developed severe headache, loss of vision of the right eye and suffered from numbness of the tongue and lumbar pain. MRI revealed extensive solid metastasis to the whole spinal cord and cerebellum and a slightly elevated CSF cell count with numerous malignant cells. After irradiation to the whole brain and to the symptomatic lesions Th11 to S3, near-continuous systemic chemotherapy with temozolomide 100 mg/m 2 day 1-5/7 and lumbar intrathecal injections of liposomal Ara-C were initiated, every 14 days for 3 months and subsequently every 28 days under protection against arachnitis by oral dexamethasone 3 4 mg for 5 days. With this regimen, the headache, numbness of the tongue and lumbar pain improved markedly and remained stable. In June 2007, the CSF cell count had fallen from 6 to 0 cells/μl, the cerebellar metastases had regressed by approximately 50%, and the spinal metastases remained stable. In August 2007, a slight ataxia developed that was caused by progression of a pre-existing intramedullar metastasis at level Th10, outside of the former radiation field. At the same time, a ventricular reservoir was implanted because of a newly occurring hydrocephalus. Unfortunately, the chemotherapy and spinal radiation had to be delayed for several weeks because of infection of the reservoir. Subsequently, the neurological status deteriorated and the patient developed paraparesis. In September 2007, control MRI showed progression of the cerebellar metastases and new supratentorial lesions. The patient died in December 2007 from tumour progression, 9.5 months after diagnosis of NM. Case 2. A 42-year old patient was diagnosed with Her2- positive breast cancer in After surgery and 6 cycles of chemotherapy with cyclophosphamide, methotrexate and 5- fluoruracil (CMF), an axillary relapse was operated in Subsequently, she received 6 cycles of paclitaxel (Taxol ), and regular trastuzumab was started. From April 2005, she received gosereline (Zoladex ) regularly. In December 2005, a relapse at the left brachial plexus was irradiated with 30 Gy. From February to December 2005, vinorelbine chemotherapy was administered. In December 2006, the patient developed bladder dysfunction and a slowly progressing paraparesis. The diagnostic workup revealed diffuse solid spinal metastases and CSF involvement with 36 cells/μl, among them numerous tumour cells (Figure 1). In March 2007, focal irradiation Th 10/11 with 30 Gy was applied, followed by near-continuous temozolomide 100 mg/m 2 day 1-5/7 and liposomal Ara-C every other week for
3 Hoffmann et al: Long-term Liposomal Ara-C with Temozolomide in Neoplastic Meningitis weeks and then every 4 weeks under protection against arachnitis by oral dexamethasone 3 4 mg for 5 days. The bladder dysfunction improved to normal function and the paraparesis stabilized with only a slight paresis of the left leg remaining. MRI showed stable spinal metastases in June The CSF cell count dropped to normal values and the CSF was free of tumour cells one single time in August 2007 (Figure 1). In November 2007, MRI showed progression of a preexisting metastasis Th 5/7. Despite rapid irradiation, the patient developed subtotal paraparesis. In December 2007, a combination of oral capecitabine and lapatinib was initiated, but had to be stopped after 1.5 cycles because of severe, uncontrollable diarrhoea. The CSF, however, was free of tumor cells one more time in February Temozolomide was started again as a palliative chemotherapy and the combination with liposomal Ara-C continued, because of persistance of malignant CSF cells, until June Because of infected gluteal ulcerations and deterioration of the general status, liposomal Ara-C was stopped after the 17th application and temozolomide after a total of 14 months of near-continuous application. In spite of intensive care of the skin ulcerations, the patient died in July 2008 from septicaemia without signs of progression of the CNS manifestation, 16.8 months after diagnosis of NM. Discussion Opinions on the value of the different treatment schedules in NM are contradictory. Radiotherapy may alleviate neurological symptoms, but is not associated with a longer survival (7). Several authors have reported good efficacy of systemic chemotherapy (21, 22). In approximately two thirds of cases, neoplastic meningitis occurs together with new or progressive systemic metastases and progression of the primary neoplasm (23). Consequently, up to half of the patients with NM die from systemic disease and not NM (22-24). The treatment of NM therefore has always to be planned as a whole concept that includes treatment of the CNS as well as the systemic disease. This is only guaranteed by systemic chemotherapy. An intravenous application that also targets the CSF space requires much higher doses to achieve adequate CSFconcentrations than intrathecal injection. A combined treatment of systemic and CSF disease can be applied with high-dose intravenous methotrexate (HD-MTX), for which favorable results have been reported (25-27). The use of HD- MTX, however, is limited in patients with relevant comorbidity and a higher rate of systemic toxicity might be expected (13, 28). The efficacy of intrathecal chemotherapy remains unclear. Several reports in the literature suggested that it improves the outcome of patients with NM (29-33). Other groups found no additional effect on survival (6, 21). In NM from solid tumours, cases of long-lasting cytological complete remission during treatment with intrathecal liposomal Ara-C have been reported (27). In randomized studies, a significantly longer time to neurological progression, but no significantly better survival, was observed with liposomal Ara-C as compared with MTX (34). This could not be confirmed in a subsequent study with both solid and haematological malignancies and different routes of application (35). In CNS metastases from breast cancer, activity of conventionally applied temozolomide (200 mg/m 2 day 1-5/28) was limited (16-18). Only in one series was some efficacy seen (36). In recurrences of malignant gliomas, we have observed better responses with a near-continuous temozolomide regimen (100 mg/m 2 day 1-5/7) despite failure of conventionally applied temozolomide (20). Although the dose per cycle is doubled with the near-continuous regimen, good haematological tolerance was seen and dose adaptation was uncomplicated. Apart from tolerance, the nearcontinuous application aims at permanent depletion of O 6 - methyl-dna-guanine-methyl transferase (MGMT), an important predictive factor in glioblastomas. In breast cancer, MGMT activity was found to be even higher than in glioma (37). We therefore also expected temozolomide to be effective in breast cancer patients through targeting MGMT by near-continuous application. Thus, temozolomide was applied in an altered, near-continuous schedule and aimed at stabilizing solid systemic and CNS metastases and at supporting the intra-csf cytotoxicity of liposomal Ara-C. The long-term treatment of both patients receiving this multimodality regimen without severe toxicity proved the feasibility of this strategy. Glas et al. reported application of 9 cycles of liposomal Ara-C in combination with whole-brain radiotherapy (WBRT) in a patient with NM from breast cancer without neurotoxicity (38). Here the feasibility of up to 17 injections of liposomal Ara-C combined with systemic temozolomide after WBRT without detectable toxicity was demonstrated, supporting the potential of long-term combination of intrathecal and systemic therapy. Individual dose adaptation of systemic temozolomide also enables the application of such a therapy to patients with critical blood counts. With this concept, the need for high-dose systemic chemotherapy with the risk of severe side-effects can be avoided and therapy can also be given to patients that would not tolerate high-dose MTX due to renal or cardiac comorbidity. The clinical improvement and stabilization was probably associated with both radiotherapy and combined systemic and intrathecal chemotherapy. Although radiotherapy is known to be of good efficacy for the improvement of symptoms, this treatment option alone is not expected to induce long-term stabilization (4, 22, 39). Both patients, however, had spinal relapses outside of the previous 5193
4 Figure 1. Overview of the radiological and cytological course (case 2) during treatment with temozolomide 100 mg/m 2 day 1-5/7 and lumbar liposomal Ara-C every 2-4 weeks. Lower panels: CSF cytology (Pappenheim, 1000). radiation field, indicating a possible long-term effect of radiation when combined with chemotherapy. The overall stabilization of 6 months, however, would most probably not have been possible without systemic chemotherapy. The additional intrathecal chemotherapy, which normalized cell counts in both patients, was considered to be an integral part of the treatment concept to control the CSF tumour cells. With the use of liposomal Ara-C, the frequency of lumbar punctures only every 2-4 weeks is reduced to a tolerable level. In conclusion, long-term stabilization or improvement in aggressively metastasizing breast cancer is possible with a multimodal treatment including near-continuous exposure of tumor cells to intrathecally and systemically applied chemotherapy. The results need to be confirmed prospectively. References 1 Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R and Winer E: Central nervous system metastases in women who receive trastuzumabbased therapy for metastatic breast carcinoma. Cancer 97: , Balm M and Hammack J: Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 53: , DeAngelis LM: Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 38: , Ongerboer de Visser, Somers R, Nooyen WH, van Heerde P, Hart AA and McVie JG: Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33: , Grossman SA and Krabak MJ: Leptomeningeal carcinomatosis. Cancer Treat Rev 25: , Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, Hart AA, Benraadt J and Vecht C: The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40: , Rudnicka H, Niwinska A and Murawska M: Breast cancer leptomeningeal metastasis the role of multimodality treatment. J Neurooncol 84: 57-62, Jayson GC and Howell A: Carcinomatous meningitis in solid tumours. Ann Oncol 7: , Chamberlain MC: Neoplastic meningitis. J Clin Oncol 23: , Chamberlain MC, Kormanik P, Howell SB and Kim S: Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52: ,
5 Hoffmann et al: Long-term Liposomal Ara-C with Temozolomide in Neoplastic Meningitis 11 Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E and Kim S: Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol 50: , Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L and Howell SB: Intrathecal treatment of neoplastic meningitis due to breast cancer with a slowrelease formulation of cytarabine. Br J Cancer 84: , Pentheroudakis G and Pavlidis N: Management of leptomeningeal malignancy. Expert Opin Pharmacother 6: , Kern DH, Morgan CR and Hildebrand-Zanki SU: In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(ii). Cancer Res 48: , Bleyer WA: Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium. Clin Cancer Res 5: , Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY and Malkin MG: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53: , Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P and Throuvalas N: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20: , Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C and Skarlos DV: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12: , Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S and Eisenhauer E: Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 17: , Strik HM, Buhk JH, Wrede A, Hoffmann A, Bock H, Chistmann M and Kaina B: Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. Molec Med Rep 1: , Bokstein F, Lossos A and Siegal T: Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82: , Boogerd W, Hart AA, van der Sande JJ and Engelsman E: Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67: , Wasserstrom WR, Glass JP and Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49: , van Oostenbrugge RJ and Twijnstra A: Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology 53: , Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P and Egorin MJ: High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16: , Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG and Raizer JJ: Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 78: , Gaviani P, Silvani A, Corsini E, Erbetta A and Salmaggi A: Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report. Neurol Sci 30: , Pavlidis N: The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann Oncol 15(Suppl 4): iv285- iv291, Chamberlain MC and Kormanik PR: Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 35: 55-64, Bruna J, Gonzalez L, Miro J, Velasco R, Gil M and Tortosa A: Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 115: , Chamberlain MC and Kormanik PA: Prognostic significance of 111 indium-dtpa CSF flow studies in leptomeningeal metastases. Neurology 46: , Chamberlain MC and Kormanik P: Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 55: , Sause WT, Crowley J, Eyre HJ, Rivkin SE, Pugh RP, Quagliana JM, Taylor SA and Molnar B: Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases a Southwest Oncology Group study. J Neurooncol 6: , Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF and Howell SB: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5: , Glantz M, Chamberlain M, Batchelor T, Eric W, Cavalli F and Shapiro W: Interaction between route of intra-csf chemotherapy administration and efficacy of therapy in patients with neoplastic meningitis. J Clin Oncol Conf Proceedings 24: 1530, Verger E, Gil M, Yaya R, Vinolas N, Villa S, Pujol T, Quinto L and Graus F: Temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61: , Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL and Rowinsky EK: Marked inactivation of O 6 -alkylguanine-dna alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88: , Glas M, Stuplich M, Tschampa H, Urbach H, Rasch K and Herrlinger U: Liposomal cytarabine given concomitantly with radiotherapy in a patient with leptomeningeal metastasis from breast cancer. J Neurol 255: , Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, Beuzeboc P, Dorval T and Pouillart P: Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors and results of a high-dose intrathecal methotrexate regimen. Cancer 77: , Received August 11, 2009 Revised October 29, 2009 Accepted November 4,
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine
doi: 10.1054/ bjoc.2000.1574, available online at http://www.idealibrary.com on http://www.bjcancer.com Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation
More informationLeptomeningeal carcinomatosis (LC) is a rare but rapidly fatal
ORIGINAL ARTICLE Leptomeningeal Carcinomatosis in Non Small-Cell Lung Cancer Patients Impact on Survival and Correlated Prognostic Factors Su Jin Lee, MD,* Jung-Il Lee, MD, PhD, Do-Hyun Nam, MD, PhD, Young
More informationINTRATHECAL APPLICATION OF MONOCLONAL ANTIBODIES. Samo Rožman Institute of Oncology Ljubljana Slovenia
INTRATHECAL APPLICATION OF MONOCLONAL ANTIBODIES Samo Rožman Institute of Oncology Ljubljana Slovenia AGENDA 1. INTRATHECAL APPLICATION 2. MONOCLONAL ANTIBODIES 3. MALIGNANT CARCINOMATOSIS 4. INTRATHECAL
More informationLeptomeningeal metastasis: management and guidelines. Emilie Le Rhun Lille, FR Zurich, CH
Leptomeningeal metastasis: management and guidelines Emilie Le Rhun Lille, FR Zurich, CH Definition of LM LM is defined as the spread of tumor cells within the leptomeninges and the subarachnoid space
More informationPage 1 of 5 DIAGNOSIS RISK STATUS TREATMENT WORKUP
Note: Consider Clinical Trials as treatment options f eligible patients. Signs and symptoms suggestive of leptomeningeal metastases Leptomeningeal Metastases WORKUP Physical exam with comprehensive neurologic
More informationliposomal cytarabine suspension (DepoCyte ) is not recommended for use within NHS Scotland for the intrathecal treatment of lymphomatous meningitis.
Scottish Medicines Consortium Re-Submission liposomal cytarabine 50mg suspension for injection (DepoCyte) No. (164/05) Napp Pharmaceuticals 6 July 2007 The Scottish Medicines Consortium (SMC) has completed
More informationLeptomeningeal Carcinomatosis: Risks, Detection, and Treatment. Goldie Kurtz, MD, FRCPC Department of Radiation Oncology University of Pennsylvania
Leptomeningeal Carcinomatosis: Risks, Detection, and Treatment Goldie Kurtz, MD, FRCPC Department of Radiation Oncology University of Pennsylvania May 13, 2016 Disclosures None to declare 2 Outline Epidemiology
More informationIntrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015 Mar 2 [Epub ahead of print] Case Report http://dx.doi.org/10.4143/crt.2014.234 Open Access Intrathecal Trastuzumab Treatment in Patients with Breast
More information3394 Vol. 5, , November 1999 Clinical Cancer Research
3394 Vol. 5, 3394 3402, November 1999 Clinical Cancer Research A Randomized Controlled Trial Comparing Intrathecal Sustainedrelease Cytarabine (DepoCyt) to Intrathecal Methotrexate in Patients with Neoplastic
More informationCNS Metastases in Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer CNS Metastases in Breast Cancer CNS Metastases in Breast Cancer Version 2006: Maass / Junkermann Version 2007 2009: Bischoff
More informationNeuro-Oncology. Neuro-Oncology 16(9), , 2014 doi: /neuonc/nou089 Advance Access date 27 May 2014
Neuro-Oncology Neuro-Oncology 16(9), 1176 1185, 2014 doi:10.1093/neuonc/nou089 Advance Access date 27 May 2014 Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationNEOPLASTIC MENINGITIS
NEOPLASTIC MENINGITIS Marc C. Chamberlain, M.D. Department of Neurology and Neurological Surgery University of Southern California Keck School of Medicine Norris Comprehensive Cancer Center and Hospital
More informationNON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
More informationCerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara
Cerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara CNS metastases in HER2+ BC The proportion of patients with HER2+ advanced breast cancer who have CNS metastases
More informationKeywords Breast cancer Brain metastasis Lapatinib Capecitabine. Introduction
Int Canc Conf J (2013) 2:9 13 DOI 10.1007/s13691-012-0054-x CASE REPORT HER2-positive recurrent breast cancer and metastases of breast cancer, including life-threatening metastases to the brain and dura
More informationConcomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
More informationTreatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer Qinghua Xu 1,6, Xiu Chen 3, Danwen Qian 4, Yongsheng
More informationScottish Medicines Consortium
Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly
More informationProlonged Survival of Patients with Breast Cancerrelated Leptomeningeal Metastases
Prolonged Survival of Patients with Breast Cancerrelated Leptomeningeal Metastases EMILIE LE RHUN 1,2, SOPHIE TAILLIBERT 3,4, FAHED ZAIRI 2, DIANE PANNIER 1, THOMAS BOULANGER 5, CHARLES ANDRE 6, JEAN LOUIS
More informationLeptomeningeal carcinomatosis from gastric cancer: single institute retrospective analysis of 9 cases
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/10.4174/astr.2014.86.1.16 Annals of Surgical Treatment and Research Leptomeningeal carcinomatosis from gastric cancer: single institute
More informationTHE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
More informationLearn about Leptomeningeal Disease
Learn about Leptomeningeal Disease Information for patients and caregivers Princess Margaret Read this resource to learn: What is leptomeningeal disease What are the symptoms of leptomeningeal disease
More informationUniversity of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationComplications associated with intraventricular chemotherapy in patients with leptomeningeal metastases
J Neurosurg 87:694 699, 1997 Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases MARC C. CHAMBERLAIN, M.D., PATTY A. KORMANIK, R.N., M.S., AND DAVID BARBA,
More informationLeptomeningeal Disease
Leptomeningeal Disease Morris D. Groves, MD, JD KEYWORDS Leptomeningeal disease Neoplastic meningitis Malignant meningitis Cancer Leptomeningeal metastasis (LMD) refers to the dissemination of cancer to
More informationRecurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports Puyuan
More informationIncidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide
405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationIntroduction. Fahed Zairi 1 Emilie Le Rhun. Sophie Taillibert 4,5 Rabih Aboukais
J Neurooncol (2015) 124:317 323 DOI 10.1007/s11060-015-1842-x CLINICAL STUDY Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM BRAIN METASTASES CNS Site Group Brain Metastases Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationSequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide
Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Review Article [1] April 01, 1997 By Clifford A. Hudis, MD [2] The recognition of paclitaxel's (Taxol's) activity
More informationMALIGNANT GLIOMAS: TREATMENT AND CHALLENGES
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN
More informationCNS TUMORS. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
CNS TUMORS D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) CNS TUMORS The annual incidence of intracranial tumors of the CNS ISmore than intraspinal tumors May be Primary or Secondary
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationCase Report Meningeal Carcinomatosis: A Metastasis from Gastroesophageal Junction Adenocarcinoma
Case Reports in Medicine Volume 2013, Article ID 245654, 4 pages http://dx.doi.org/10.1155/2013/245654 Case Report Meningeal Carcinomatosis: A Metastasis from Gastroesophageal Junction Adenocarcinoma Tanya
More informationNeoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases
Therapeutic options for neoplastic meningitis include systemic therapy, the intra-csf administration of chemotherapy, and CNS site-specific radiotherapy. Julie Gilbert Pollard. Box Canyon. Oil on canvas,
More informationReferring to Part of the Dossier. Protocol No.: DEP1501 EudraCT/IND No.:
2. SYNOPSIS Name of Sponsor: Mundipharma Research Limited Name of Finished Product: epocyte Name of Active Ingredient: Cytarabine Liposome Injection INIVIUAL STUY TABLE Referring to Part of the ossier
More informationIntrathecal chemotherapy for refractory. for disseminated medulloblastoma. ORIGINAL PAPER
DOI 10.1007/s00381-007-0538-8 ORIGINAL PAPER Intrathecal chemotherapy for refractory disseminated medulloblastoma Junichi Yoshimura & Kenichi Nishiyama & Hiroshi Mori & Hideaki Takahashi & Yukihiko Fujii
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationBrain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland
Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients
More informationAddressing Brain Metastases in HER2-Positive Breast Cancer
Addressing Brain Metastases in HER2-Positive Breast Cancer Carlos Barrios, MD PUCRS School of Medicine Instituto do Câncer Hospital Mãe de Deus Latin American Clinical Oncology Group (LACOG) Porto Alegre,
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationSensitivity and specificity of single and combined
Journal of Neurology, Neurosurgery, and Psychiatry 1986;49:1246-1250 Sensitivity and specificity of single and combined tumour markers in the diagnosis of leptomeningeal metastasis from breast cancer A
More informationAdvancements in diagnosis and treatment of meningeal carcinomatosis in solid cancer
Neuroimmunol Neuroinflammation 2017;4:167-78 DOI: 10.20517/2347-8659.2017.26 Topic: Infectious Disease of Central Nervous System Neuroimmunology and Neuroinflammation www.nnjournal.net Open Access Advancements
More informationClinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: PA.CP.MP.145
Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: PA.CP.MP.145 Effective Date: 01/18 Last Review Date: 04/18 Coding Implications Revision Log Description Electric tumor treating
More informationThe use of surgery in the elderly. for management of metastatic epidural spinal cord compression
The use of surgery in the elderly Bone Tumor Simulators for management of metastatic epidural spinal cord compression Justin E. Bird, M.D. Assistant Professor Orthopaedic Oncology and Spine Surgery Epidemiology
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
More informationFactors influencing survival in patients with breast cancer and single or solitary brain metastasis
Factors influencing survival in patients with breast cancer and single or solitary brain metastasis A. Niwińska, K. Pogoda, M. Murawska, P. Niwiński To cite this version: A. Niwińska, K. Pogoda, M. Murawska,
More informationAppraisal of carmustine. implants and temozolomide. for newly diagnosed high. Brain and Spine Foundation
Appraisal of carmustine implants and temozolomide for newly diagnosed high grade glioma Brain and Spine Foundation June 2005 Submission to the National Institute for Health and Clinical Excellence Brain
More informationCerebrospinal Fluid Cytology and Clinical Analysis of 34 Cases with Leptomeningeal Carcinomatosis
The Journal of International Medical Research 2009; 37: 1913 1920 Cerebrospinal Fluid Cytology and Clinical Analysis of 34 Cases with Leptomeningeal Carcinomatosis J LIU*, H JIA*, Y YANG, W DAI, X SU ANDG
More informationDose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
J Neurooncol (2012) 108:195 200 DOI 10.1007/s11060-012-0832-5 CLINICAL STUDY Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study Walter Taal Joyce M. W. Segers-van Rijn
More informationCase Report Three Cases of Neoplastic Meningitis Initially Diagnosed with Infectious Meningitis in Emergency Department
Case Reports in Emergency Medicine Volume 2013, Article ID 561475, 4 pages http://dx.doi.org/10.1155/2013/561475 Case Report Three Cases of Neoplastic Meningitis Initially Diagnosed with Infectious Meningitis
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
More informationCarmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
More informationSpinal cord compression as a first presentation of cancer: A case report
J Pain Manage 2013;6(4):319-322 ISSN: 1939-5914 Nova Science Publishers, Inc. Spinal cord compression as a first presentation of cancer: A case report Nicholas Lao, BMSc(C), Michael Poon, MD(C), Marko
More informationClinically, leptomeningeal disease (LMD) occurs in
CASE REPORT Endocrine Therapy for Leptomeningeal Metastases from ER-Positive Breast Cancer: Case Report and a Review of the Literature Behyar Zoghi, MD, PhD and Richard Elledge, MD University of Texas
More informationGoing Past the Data for Temozolomide. J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D.
Going Past the Data for Temozolomide J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D. Departments of Medicine (JLV), Neurosurgery (JLV) and Pharmacy Practice (LRB)
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MEDULLOBLASTOMA AND PNET CNS Site Group Medulloblastoma and PNET Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationFeasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma ABSTRACT Recurrent or progressive pediatric CNS tumors generally have a poor prognosis
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More informationNCCN Guidelines for Central Nervous System Cancers V Follow-Up on 02/23/18
GLIO-3 and GLIO-4 Submission from Novocure Inc. (12/19/17 and 9/7/17) Please consider adding tumor treating fields in combination with temozolomide for the treatment of adult patients with newly diagnosed,
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More informationCase Report Tackling a Recurrent Pinealoblastoma
Case Reports in Oncological Medicine, Article ID 135435, 4 pages http://dx.doi.org/10.1155/2014/135435 Case Report Tackling a Recurrent Pinealoblastoma Siddanna Palled, 1 Sruthi Kalavagunta, 1 Jaipal Beerappa
More informationCorporate Medical Policy
Corporate Medical Policy Brachytherapy, Intracavitary Balloon Catheter for Brain Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_intracavitary_balloon_catheter_for_brain_cancer
More informationSelected radiosurgery cases from the Rotating Gamma Institute Debrecen, Hungary
Selected radiosurgery cases from the Rotating Gamma Institute Debrecen, Hungary László Bognár M.D., Ph.D., József G. Dobai M.D., Gábor Csiky and Imre Fedorcsák M.D., Ph.D. Department of Neurosurgery, Medical
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationResearch Article Meningeal Melanomatosis: A Challenge for Timely Diagnosis
BioMed Research International Volume 2015, Article ID 948497, 6 pages http://dx.doi.org/10.1155/2015/948497 Research Article Meningeal Melanomatosis: A Challenge for Timely Diagnosis Giulia Berzero, 1,2
More informationEribulin for locally advanced or metastatic breast cancer third line; monotherapy
Eribulin for locally advanced or metastatic breast cancer third line; monotherapy April 2009 This technology summary is based on information available at the time of research and a limited literature search.
More informationIntrathecal chemotherapy as a treatment for leptomeningeal metastasis of non small cell lung cancer: A pooled analysis
ONCOLOGY LETTERS 12: 1301-1314, 2016 Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non small cell lung cancer: A pooled analysis YA LAN WU 1-3, LIN ZHOU 2,3 and YOU LU 2,3 1
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationClinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases
Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases Ying Zhou 1#, Kefang Zhong 1#, Fang Zhou* 2 ABSTRACT This paper aims to explore the clinical features and prognostic
More informationRadiotherapy of Brain Metastases and Carcinomatous Meningitis
Universitätsspital Basel Radiotherapy of Brain Metastases and Carcinomatous Meningitis Dr. J. Winkler 16.01.2009 1 in 4 cancer patients develop brain metastases In 1/3-1/2 of these patients brain metastasis
More informationGamma Knife Radiosurgery A tool for treating intracranial conditions. CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop
Gamma Knife Radiosurgery A tool for treating intracranial conditions CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop ANGELA McBEAN Gamma Knife CNC State-wide Care Coordinator Gamma Knife
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationINDIAN JOURNAL OF CANCER
THE INDIAN JOURNAL OF CANCER ISSN 0019-509X Volume 44 Issue 3 July September 2007 C O N T E N T S ORIGINAL ARTICLES Clinico-biologic profi le of Langerhans cell histiocytosis: A single institutional study
More informationClinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
More informationLocal radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions
Original Article Radiat Oncol J 2016;34(1):59-63 pissn 2234-1900 eissn 2234-3156 Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions Jeong Won Lee, MD, Jeong Eun
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 7 MARCH 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Results of Whole-Brain Radiation As Salvage of Methotrexate Failure for Immunocompetent Patients With Primary CNS
More informationForm 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationOncothermia application for various malignant diseases
Oncothermia Journal 7:260-265 (2013) Oncothermia application for various malignant diseases Youngsuk Lee 1 (1) Good World Anti Cancer Center; 542-6 Dogok-dong, Gangnam-gu, Seoul, Korea; lysos1128@naver.com
More informationNeurologic complications in small cell lung cancer. Tatjana Seute
Neurologic complications in small cell lung cancer Tatjana Seute The copyright of articles that have already been published or have been accepted for publication has been transferred to the respective
More informationSurgery, RT, CHT have increased curability Precocious diagnosis and adequate FU have permitted early diagnoses of primary and relapses Cronicization
Surgery, RT, CHT have increased curability Precocious diagnosis and adequate FU have permitted early diagnoses of primary and relapses Cronicization is the goal in a lot of patients The hope of target
More informationHorizon Scanning Technology Summary. Temozolomide (Temodal) for advanced metastatic melanoma. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Temozolomide (Temodal) for advanced metastatic melanoma April 2007 This technology summary is based on information available at the
More informationChallenging Paediatric Brain Tumours. ASP Belfast March 2017 Dr Jane Pears Consultant Paediatric Oncologist, Dublin
Challenging Paediatric Brain Tumours ASP Belfast March 2017 Dr Jane Pears Consultant Paediatric Oncologist, Dublin Overview (i) Paediatric malignancy (ii) Central nervous system tumours (iii) Diffuse Intrinsic
More informationMR Imaging of Leptomeningeal Metastases: Comparison of Three Sequences
AJNR Am J Neuroradiol 23:817 821, May 2002 MR Imaging of Leptomeningeal Metastases: Comparison of Three Sequences Sanjay K. Singh, Norman E. Leeds, and Lawrence E. Ginsberg BACKGROUND AND PURPOSE: Recent
More informationCase 7391 Intraventricular Lesion
Case 7391 Intraventricular Lesion Bastos Lima P1, Marques C1, Cabrita F2, Barbosa M2, Rebelo O3, Rio F1. 1Neuroradiology, 2Neurosurgery, 3Neuropathology, Coimbra University Hospitals, Portugal. University
More informationPRIMARY CNS lymphoma (PCNSL) is a rare non-
Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96 07 By Tracy Batchelor, Kathryn Carson, Alison O Neill, Stuart A. Grossman, Jane Alavi, Pamela New, Fred
More informationSociety for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
More informationCitation Pediatrics international (2015), 57.
Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation
More informationManagement of carcinomatous meningitis in a patient with advanced lung adenocarcinoma
Management of carcinomatous meningitis in a patient with advanced lung adenocarcinoma Clinical Case Presentation Emilie Le Rhun Centre Hospitalier Régional et Universitaire (CHRU) de Lille Neurochirurgie
More informationThe Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
More informationTheodore S. Johnson, MD, PhD
Front-line Therapy of DIPG Using IDO Pathway Inhibitor Indoximod in Combination with Radiation and Chemotherapy American Association of Cancer Research (AACR) 2018 Theodore S. Johnson, MD, PhD Georgia
More informationA PATIENT WITH TWO EPISODES OF THORACIC SPINAL CORD COMPRESSION CAUSED BY PRIMARY LYMPHOMA AND METASTATIC CARCINOMA OF THE PROSTATE, 11 YEARS APART
A PATIENT WITH TWO EPISODES OF THORACIC SPINAL CORD COMPRESSION CAUSED BY PRIMARY LYMPHOMA AND METASTATIC CARCINOMA OF THE PROSTATE, 11 YEARS APART Shih-Huang Tai, 1 Yu-Chang Hung, 1 Jian-Chin Chen, 2
More information